Systems Biology Opens the Blackest Boxes
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
En banc oral arguments about a pair of Federal Circuit cases are being closely watched by the biopharma industry. Stakeholders are seeking clearer direction on when patents can be considered jointly infringed. Earlier this year, separate Federal Circuit panels held there was no viable legal theory to support findings that defendants in the two cases engaged in joint infringement, despite a contractual relationship in Akamai Technologies, Inc. v. Limelight Networks, Inc. and a doctor/patient relationship in McKesson Technologies Inc. v. Epic System Corp. More information can be found here. BIO, PhRMA, and Myriad Genetics support the plaintiffs, Akamai and McKesson, and assert that current stipulations of joint infringement could be detrimental to personalized medicine.